- Investing Ideas
- Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Results
6
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
6 companies
Zhejiang Medicine
Market Cap: CN¥11.5b
Manufactures and sells life nutrition and pharmaceuticals products in China and internationally.
600216
CN¥12.17
7D
2.1%
1Y
-19.9%
Zhejiang Garden BiopharmaceuticalLtd
Market Cap: CN¥8.0b
Zhejiang Garden Biopharmaceutical Co.,Ltd.
300401
CN¥14.69
7D
35.0%
1Y
7.2%
Aurisco PharmaceuticalLtd
Market Cap: CN¥7.9b
Engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide.
605116
CN¥19.58
7D
6.6%
1Y
-10.3%
Shandong Wit Dyne HealthLtd
Market Cap: CN¥6.5b
Engages in the pharmaceutical business in China.
000915
CN¥27.72
7D
3.9%
1Y
-4.3%
Hunan Fangsheng Pharmaceutical
Market Cap: CN¥4.3b
Engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China.
603998
CN¥9.73
7D
0.8%
1Y
-7.8%
Bide Pharmatech
Market Cap: CN¥3.9b
Engages in the research, development, production, and sale of pharmaceutical products in China.
688073
CN¥44.99
7D
-2.0%
1Y
-8.0%